Baum RP, Zhang J, Schuchardt C, Muller D, et al. First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med 2021;62:1571-1581.
PMID: 33674401